{"id":55229,"date":"2026-01-23T06:07:55","date_gmt":"2026-01-22T22:07:55","guid":{"rendered":"https:\/\/flcube.com\/?p=55229"},"modified":"2026-01-23T06:07:56","modified_gmt":"2026-01-22T22:07:56","slug":"bio-sincerity-pharma-tech-secures-greater-china-priority-rights-for-delims-semaglutide-and-tirzepatide-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55229","title":{"rendered":"Bio\u2011Sincerity Pharma\u2011Tech Secures Greater China Priority Rights for Delim\u2019s Semaglutide and Tirzepatide Portfolio"},"content":{"rendered":"\n

Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd.<\/strong> (SHE: 301096<\/a>) announced a strategic cooperation agreement with Delim Cosmetics & Pharma S.R.L.<\/strong>, granting Bio\u2011Sincerity priority rights<\/strong> for Delim\u2019s high\u2011value marketed products in Greater China<\/strong>. The initial collaboration focuses on innovative oral formulations<\/strong> of semaglutide, tirzepatide, and Minoxidil<\/strong>, covering full lifecycle from R&D through commercialization.<\/p>\n\n\n\n

Partnership Structure & Strategic Terms<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Partners<\/strong><\/td>Bio\u2011Sincerity Pharma\u2011Tech (301096.SZ) \/ Delim Cosmetics & Pharma S.R.L.<\/td><\/tr>
Territory<\/strong><\/td>Greater China \u2013 exclusive priority cooperation rights<\/td><\/tr>
Product Focus<\/strong><\/td>Semaglutide, tirzepatide, Minoxidil (innovative oral formulations)<\/td><\/tr>
Scope<\/strong><\/td>Research, development, production, and commercialization<\/td><\/tr>
Deal Type<\/strong><\/td>Strategic cooperation agreement<\/td><\/tr>
Significance<\/strong><\/td>Expands Bio\u2011Sincerity\u2019s metabolic and dermatology pipeline with blockbuster\u2011caliber assets<\/td><\/tr>
Timeline<\/strong><\/td>Initial phase targeting priority product development and regulatory filing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Portfolio & Market Position<\/h2>\n\n\n\n